Swiss S1 guideline for the treatment of rosacea

Anzengruber, Florian; Czernielewski, J.; Conrad, Curdin; Feldmeyer, Laurence; Yawalkar, Nikhil; Häusermann, Peter; Cozzio, Antonio; Mainetti, Carlo; Goldblum, David; Läuchli, Severin; Imhof, Laurence; Brand, C. U.; Laffitte, Emmanuel; Navarini, Alexander A.

doi:10.1111/jdv.14349

Cited by 59 publications

(82 citation statements)

References 217 publications

(277 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with IGA 1 and IGA 2 rosacea had fewer inflammatory lesions count than patients with IGA 3‐4 rosacea, so we suppose that they reached more easily IGA = 0. Moreover, we assume that ivermectin is useful to achieve an effective result (IGA ≤ 1) in the IGA 3‐4 patient group, but it should be associated with other treatments in order to reach IGA = 0, as recommended in guidelines (Anzengruber et al, ; Asai et al, ; Reinholz et al, ). In fact, clinical evidence and guidelines support that an intensified initial treatment with two agents would be more effective in patients with severe disease than others (Steinhoff et al, ).…”

Section: Discussionmentioning

confidence: 99%

“…Up to now, ivermectin has only been tested in moderate‐to‐severe PPR, and studies concerning its use on almost clear mild forms are lacking (Sahni, Feldman, & Taylor, ). However, clinical guidelines recommend the use of topical ivermectin alone as the first‐line treatment in patients with a mild presentation and alternatively in combination therapy in severe PPR (Anzengruber et al, ; Asai et al, ; Schaller, Dirschka, Kemény, Briantais, & Jacovella, ; Schaller, Schöfer, et al, ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real‐life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites

Trave

Merlo

Cozzani

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Ivermectin is a drug approved for the treatment of papulopustular rosacea (PPR). Although clinical guidelines recommend the use of ivermectin as the first‐line treatment in patients with almost clear and mild rosacea, studies concerning its use on them are lacking. This study investigated the effectiveness and the tolerability of ivermectin in almost clear to severe rosacea and assessed the antiparasitic effect on Demodex mites. This is a retrospective study based on 50 patients affected by PPR and treated with topical ivermectin 1% once daily over 16 weeks. The disease severity, the patient‐examined improvement, and the safety assessment of patients were evaluated. Demodex mites were studied with the standardized skin surface biopsy. PPR to all severity achieved a therapeutic success. The number of inflammatory lesions was significantly decreased in almost clear (p < .0001), mild, moderate, and severe (p < .001) forms. A complete remission of inflammatory lesions was achieved by almost clear (p < .001) and mild (p = .005) with 82% with none‐to‐mild cutaneous adverse events. Thirty‐two percent were positive for Demodex mites, and all of them turned negative after 16 weeks. Ivermectin is an effective treatment not only in moderate to severe PPR but also in almost clear/mild rosacea.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Real‐life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites

Trave

Merlo

Cozzani

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…(3) overproduction of antimicrobial peptides (AMPs) by congenital immune system such as LL-37; (4) ROS-induced inflammation produced by adaptive immune cells; (5) overexpression of toll-like receptors (TLRs); (6) Demodex folliculorum-induced inflammations; and (7) neuroinflammation and vascular hyperactivity [132,133].…”

Section: Rosaceamentioning

confidence: 99%

Chalcones in Dermatology

Jumina¹,

Harizal²,

Kurniawan³

2021

Beauty - Cosmetic Science, Cultural Issues and Creative Developments

View full text Add to dashboard Cite

The human skin is pivotal for protecting the body from various stresses and diseases, regulating several physiological aspects, and sensing any signal changes around the environment. To work and function optimally, the skin should be protected and cared regularly by using some treatments. Chalcone, as a privileged structure, exhibits wide and unique bioactivities related to several skin disorders such as in preventing and treating pigmentation disorders (melasma and vitiligo), cutaneous leishmaniasis, rashes (acne vulgaris, seborrheic dermatitis and dandruff, psoriasis and atopic dermatitis), and rosacea. In this chapter, the role of chalcone derivatives in treating several skin disorders as mentioned above is discussed to provide a brief and comprehensive perspective regarding the role of chalcone in dermatology including in vitro, preclinical, and clinical assays.

show abstract

“…Many drugs and methods can be used in the treatment of rosacea. In the past three years, there have been 4 international and domestic publications of rosacea treatment guidelines or expert consensus, which include 2016 China Rosacea Consensus, 2016 Canada Clinical practice guideline, 2017 Swiss S1 guideline, and 2017 Global Rosacea Consensus (ROSCO) …”

Section: Introductionmentioning

confidence: 99%

Global rosacea treatment guidelines and expert consensus points: The differences

Juliandri

Wang

Liu

et al. 2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Summary Background Rosacea is a highly prevalent, chronic inflammatory disease. The treatment of rosacea remains a challenge to dermatologists. Therapies include skin care, medications, lasers, and various combinations of these modalities. The appropriate treatment depends on clinical types and patient's various clinical symptoms. Purpose The purpose of this study was to review and compare current therapies for rosacea of all severities from four different guidelines. Methodology We searched PubMed using the keywords “rosacea,” “treatment” AND [“erythema rosacea” OR “papulopustular rosacea” OR “ocular rosacea” OR “phymatous rosacea”]. We selected randomized controlled trials, observational studies, controlled clinical trials, and clinical trials. We indentified further studies (including the guidelines) by hand‐searching relevant publications and included those that met the inclusion criteria. Results The total number of records identified was 421. We limited our search to the specific abovementioned study types. Twenty‐five of these studies met with our inclusion criteria. An additional five manuscripts were selected using the abovementioned method, and four guidelines were included in this review. Conclusion Diagnosing and choosing the appropriate treatment options of rosacea according to guidelines is the basis of scientific criteria. More large‐scale randomized controlled clinical trials on new treatment methods, new drugs, or new dosage forms provide a new guideline for future rosacea treatment. Although there are some differences in the treatment of rosacea, it is generally based on anti‐demodex, anti‐inflammatory, and anti‐angiogenesis.

show abstract

Swiss S1 guideline for the treatment of rosacea

Cited by 59 publications

References 217 publications

Real‐life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites

Real‐life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites

Chalcones in Dermatology

Global rosacea treatment guidelines and expert consensus points: The differences

Contact Info

Product

Resources

About